We are live on !
Find out more
Stanley-Laman Group Portfolio holdings
AUM
$915M
Turnover
11.67%
1-Year Est. Return
50.26%
This Fund
S&P 500
This Quarter Est. Return
-2.79%
1 Year Est. Return
+50.26%
3 Year Est. Return
+113.93%
5 Year Est. Return
+106.15%
10 Year Est. Return
+368.2%
AUM
$915M
AUM Growth
-$69.1M
(-7%)
Cap. Flow
-$11.3M
Cap. Flow % of AUM
Cap. Flow %
-1.24%
Top 10 Holdings %
Top 10 Hldgs %
19.78%
Holding
317
New
19
Increased
50
Reduced
138
Closed
18
Avg Time Held
2.3
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$6.86M |
| 2 |
Glacier Bancorp
GBCI
|
+$5.86M |
| 3 |
MNTN Inc
MNTN
|
+$4.47M |
| 4 |
The Mosaic Company
MOS
|
+$4.43M |
| 5 |
Fifth Third Bancorp
FITB
|
+$2.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lantheus
LNTH
|
+$7.54M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$4.82M |
| 3 |
Zeta Global
ZETA
|
+$4.57M |
| 4 |
Hartford Financial Services
HIG
|
+$4.52M |
| 5 |
GXO Logistics
GXO
|
+$4.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.13% |
| 2 | Miscellaneous | 15.81% |
| 3 | Industrials | 11.61% |
| 4 | Energy | 8.7% |
| 5 | Healthcare | 6.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Seagate
STX
$117B
| $8.03M | 0.88% |
8,709
-54
| -0.6% | -$46.1K |
2026 Q2
1 quarter
|
|
27
Valaris
VAL
$5.5B
| $8.01M | 0.88% |
102,044
-2,902
| -3% | -$237K |
2024 Q1
10 quarters
|
|
28
Eli Lilly
LLY
$1.25T
| $7.68M | 0.84% |
6,638
-109
| -2% | -$129K |
2020 Q3
24 quarters
|
|
29
Corcept Therapeutics
CORT
$8.1B
| $7.65M | 0.84% |
66,365
-1,831
| -3% | -$197K |
2025 Q3
4 quarters
|
|
30
Vanguard S&P 500 ETF
VOO
$1.04T
| $7.21M | 0.79% |
10,292
+64
| +0.6% | +$44.7K |
2016 Q1
42 quarters
|
|
31
Mastercard
MA
$575B
| $7.1M | 0.78% |
12,868
-253
| -2% | -$142K |
2021 Q4
19 quarters
|
|
32
Vertiv
VRT
$77.1B
| $6.87M | 0.75% |
28,490
-144
| -0.5% | -$39.2K |
2025 Q3
4 quarters
|
|
33
Jabil
JBL
$26B
| $6.84M | 0.75% |
23,847
-563
| -2% | -$180K |
2024 Q2
9 quarters
|
|
34
Valero Energy
VLO
$100B
| $6.83M | 0.75% |
17,608
-4,099
| -19% | -$1.38M |
2021 Q1
22 quarters
|
|
35
Everpure Inc
P
$34.7B
| $6.58M | 0.72% |
50,351
-8,915
| -15% | -$840K |
2022 Q4
15 quarters
|
|
|
36
Madrigal Pharmaceuticals
MDGL
$9.9B
| $6.54M | 0.72% |
+12,984
| New | +$6.86M |
2026 Q3
0 quarters
|
|
37
CVS Health
CVS
$109B
| $6.03M | 0.66% |
70,316
-1,561
| -2% | -$153K |
2014 Q1
50 quarters
|
|
38
TD Synnex
SNX
$18.4B
| $6.02M | 0.66% |
23,433
-458
| -2% | -$117K |
2023 Q3
12 quarters
|
|
39
Parker-Hannifin
PH
$121B
| $5.95M | 0.65% |
6,226
-167
| -3% | -$164K |
2018 Q2
33 quarters
|
|
40
Weatherford International
WFRD
$6.28B
| $5.84M | 0.64% |
74,281
-2,131
| -3% | -$186K |
2024 Q4
7 quarters
|
|
41
Take-Two Interactive
TTWO
$39.6B
| $5.79M | 0.63% |
27,911
-441
| -2% | -$102K |
2020 Q4
23 quarters
|
|
42
SLB Ltd
SLB
$74.8B
| $5.54M | 0.61% |
113,697
-2,474
| -2% | -$127K |
2022 Q3
16 quarters
|
|
43
Archer Daniels Midland
ADM
$33.5B
| $5.41M | 0.59% |
68,113
-1,097
| -2% | -$89.9K |
2017 Q2
37 quarters
|
|
44
Boeing
BA
$137B
| $5.29M | 0.58% |
28,423
-660
| -2% | -$142K |
2020 Q4
23 quarters
|
|
45
Interactive Brokers
IBKR
$35.4B
| $5.27M | 0.58% |
61,713
-1,044
| -2% | -$95.5K |
2024 Q3
8 quarters
|
|
|
46
Glacier Bancorp
GBCI
$6.39B
| $5.24M | 0.57% |
+121,188
| New | +$5.86M |
2026 Q3
0 quarters
|
|
47
TETRA Technologies
TTI
$911M
| $5.11M | 0.56% |
871,163
-18,860
| -2% | -$145K |
2022 Q4
15 quarters
|
|
48
McKesson
MCK
$123B
| $5.11M | 0.56% |
5,980
-163
| -3% | -$140K |
2023 Q1
14 quarters
|
|
49
Marten Transport
MRTN
$983M
| $5.05M | 0.55% |
390,996
+120,551
| +45% | +$1.82M |
2026 Q1
2 quarters
|
|
50
Amgen
AMGN
$251B
| $5.04M | 0.55% |
11,946
-281
| -2% | -$112K |
2024 Q2
9 quarters
|
|
Similar funds
Stanley-Laman Group's Q3 2026 Portfolio in Review
As of Q3 2026, Stanley-Laman Group held 317 positions worth $915M, down 7% from $984M the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Stanley-Laman Group's Q3 2026 filing shows 19 new, 50 increased, 138 reduced and 18 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 12,984 shares worth $6.54M. The largest sale was Lantheus, an estimated $7.54M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 37% a quarter earlier, followed by Miscellaneous and Industrials.
- Stanley-Laman Group's largest Q3 2026 buy was Madrigal Pharmaceuticals: 12,984 shares worth $6.54M.
- Stanley-Laman Group added most to Marten Transport in Q3 2026, an estimated $1.82M increase.
- Stanley-Laman Group's biggest Q3 2026 reduction was AAR Corp, cutting an estimated $2.12M.
- Stanley-Laman Group fully exited Lantheus in Q3 2026, selling an estimated $7.54M.
- Stanley-Laman Group's ten largest holdings make up 20% of its $915M portfolio in Q3 2026.
- Stanley-Laman Group opened 19 new positions and closed 18 in Q3 2026.
- Stanley-Laman Group's portfolio value fell 7% quarter-over-quarter to $915M.
Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.